このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Instem 将来の成長

Future 基準チェック /16

Instemの収益は成長。EPSは成長すると35.8%年率で予測されます。

主要情報

n/a

収益成長率

35.8%

EPS成長率

Healthcare Services 収益成長	25.7%
収益成長率	11.4%
将来の株主資本利益率	10.4%
アナリストカバレッジ	Low
最終更新日	30 Aug 2023

今後の成長に関する最新情報

Recent updates

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 03

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

Jan 29

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Dec 25

業績と収益の成長予測

AIM:INS - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	82	N/A	11	17	2
12/31/2024	74	N/A	7	11	2
12/31/2023	65	N/A	6	10	2
6/30/2023	62	3	5	8	N/A
3/31/2023	60	4	4	8	N/A
12/31/2022	59	5	4	8	N/A
9/30/2022	56	3	4	7	N/A
6/30/2022	53	2	4	7	N/A
3/31/2022	50	2	5	8	N/A
12/31/2021	46	2	7	9	N/A
9/30/2021	40	2	6	8	N/A
6/30/2021	34	2	5	7	N/A
3/31/2021	31	2	5	7	N/A
12/31/2020	28	2	6	7	N/A
9/30/2020	28	1	5	6	N/A
6/30/2020	28	0	4	5	N/A
3/31/2020	27	0	4	5	N/A
12/31/2019	26	-1	4	5	N/A
9/30/2019	25	0	3	5	N/A
6/30/2019	24	2	2	4	N/A
3/31/2019	23	2	1	3	N/A
12/31/2018	23	1	1	2	N/A
9/30/2018	22	1	2	3	N/A
6/30/2018	21	1	3	4	N/A
3/31/2018	21	1	1	3	N/A
12/31/2017	21	1	0	1	N/A
9/30/2017	20	0	-1	1	N/A
6/30/2017	20	0	-2	0	N/A
3/31/2017	19	1	N/A	0	N/A
12/31/2016	18	1	N/A	0	N/A
9/30/2016	18	0	N/A	1	N/A
6/30/2016	18	-1	N/A	2	N/A
3/31/2016	17	0	N/A	2	N/A
12/31/2015	16	0	N/A	3	N/A
9/30/2015	16	0	N/A	N/A	N/A
6/30/2015	15	1	N/A	1	N/A
3/31/2015	14	1	N/A	1	N/A
12/31/2014	13	0	N/A	0	N/A
9/30/2014	13	0	N/A	N/A	N/A
6/30/2014	12	0	N/A	1	N/A
3/31/2014	11	0	N/A	1	N/A
12/31/2013	11	1	N/A	2	N/A
9/30/2013	11	1	N/A	1	N/A
6/30/2013	11	1	N/A	1	N/A
3/31/2013	11	1	N/A	0	N/A
12/31/2012	11	1	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: INSの予測収益成長が貯蓄率 ( 1.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: INSの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: INSの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: INSの収益 ( 11.4% ) UK市場 ( 3.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: INSの収益 ( 11.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: INSの自己資本利益率は、3年後には低くなると予測されています ( 10.4 %)。

Instem 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target increased to UK£10.10

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Recent updates

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today

New minor risk - Earnings quality

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Ennov SA acquired Samarind Ltd from Instem plc (AIM:INS).

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Price target increased to UK£10.10

Less than half of directors are independent

Instem Unveils New Additions to Its Leading Computational Toxicology Software Suite

First half 2022 earnings released: EPS: UK£0.057 (vs UK£0.048 in 1H 2021)

Instem plc Announces Settlement of Historical Licence Dispute

Instem plc to Report First Half, 2022 Results on Sep 27, 2022

Instem plc, Annual General Meeting, Jun 09, 2022

European Medicines Agency Awards Research Grant to Instem

Instem plc Receives European Medicines Agency Research Grant

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Instem plc to Report Fiscal Year 2021 Results on Apr 26, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director exercised options and sold UK£298k worth of stock

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate

Instem plc Announces the Release of the Latest Edition of Its Leadscope Model Applier Computational Toxicology Software Solution

First half 2021 earnings released: EPS UK£0.048 (vs UK£0.095 in 1H 2020)

Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd. for CHF 14.2 million.

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd for CHF 14.2 million.

Full year 2020 earnings released: EPS UK£0.12 (vs UK£0.057 loss in FY 2019)

Instem plc (AIM:INS) acquired The Edge Software Consultancy Ltd. for £8.5 million.

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

New 90-day high: UK£5.20

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

New 90-day high: UK£5.08

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Instem plc Provides New Business Update

Instem Launches in Silico Toxicology Service

New 90-day low: UK£4.40

First half earnings released

New 90-day high - UK£5.45

Instem plc has completed a Follow-on Equity Offering in the amount of £15.750002 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘